Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies - Sorbonne Université
Article Dans Une Revue The Lancet Année : 2018

Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies

Fichier non déposé

Dates et versions

hal-03777527 , version 1 (14-09-2022)

Identifiants

Citer

Martin Gartland, Michael Aboud, Josep M Llibre, Chien-Ching Hung, Cynthia Brinson, et al.. Efficacy, Safety, and Tolerability of Dolutegravir-Rilpivirine for the Maintenance of Virological Suppression in Adults with HIV-1: Phase 3, Randomised, Non-Inferiority SWORD-1 and SWORD-2 Studies. The Lancet, 2018, 391 (10123), pp.839--849. ⟨10.1016/S0140-6736(17)33095-7⟩. ⟨hal-03777527⟩
18 Consultations
0 Téléchargements

Altmetric

Partager

More